Deerfield Management Company, L.P. (Series C) Pyxis Oncology, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 16, 2022	SELL	$4.04 - $11.43 $1.26 Million - $3.56 Million	-311,754 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.39 - $13.64 $2.62 Million - $4.25 Million	311,754 New	311,754 $3.42 Million

Others Institutions Holding PYXS

# of Institutions

101

Shares Held

28.2M

Call Options Held

539K

Put Options Held

54.1K

Deep Track Capital, LP Greenwich, CT

4.18M
Shares

$8.33 Million
0.57% of portfolio
Laurion Capital Management LP New York, NY

3.63M
Shares

$7.22 Million
0.18% of portfolio
Black Rock Inc. New York, NY

2.79M
Shares

$5.54 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.43M
Shares

$4.84 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

1.91M
Shares

$3.79 Million
0.0% of portfolio

View Full List

About Pyxis Oncology, Inc.

Ticker PYXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,096,400
Market Cap $69.8M
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...

More about PYXS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account